GDD3898
Obesity
Key Facts
About Lipidio Pharmaceuticals
Lipidio Pharmaceuticals is a San Diego-based biotech with a unique platform focused on the skin's endocrine functions to treat metabolic and dermatological conditions. The company's lead program, GDD3898, is in Phase 2 development for obesity and sebaceous hyperplasia, leveraging existing clinical data to accelerate development. Led by a seasoned team with a strong track record in drug development and venture capital, Lipidio operates as a private, pre-revenue entity seeking to validate its novel therapeutic hypothesis in the large and competitive obesity market.
View full company profileAbout Lipidio Pharmaceuticals
Lipidio Pharmaceuticals is a San Diego-based biotech with a unique platform focused on the skin's endocrine functions to treat metabolic and dermatological conditions. The company's lead program, GDD3898, is in Phase 2 development for obesity and sebaceous hyperplasia, leveraging existing clinical data to accelerate development. Led by a seasoned team with a strong track record in drug development and venture capital, Lipidio operates as a private, pre-revenue entity seeking to validate its novel therapeutic hypothesis in the large and competitive obesity market.
View full company profileTherapeutic Areas
Other Obesity Drugs
| Drug | Company | Phase |
|---|---|---|
| LET003 | Harbour BioMed | Discovery |
| LET001 | Harbour BioMed | Discovery |
| RGT-075 | Regor Therapeutics | Phase 2b |
| Anti‑Obesity Oral Drug | Premas Biotech | Phase 1 |
| Obesity Target Discovery Collaboration | Fauna Bio | Target Discovery/Preclinical |
| GLP-1 variants | Heligenics | Discovery |
| MYO Platform (Metabolic Disease) | Renbio | Pre-clinical |
| Obesity Clinical Trials | IMA Clinical Research | Not Applicable (Service) |
| KAYO-2000 | KayoThera | Preclinical |
| MVD-1 (SANA) | Eolo Pharma | Phase 1 |
| GIP-neutralizing antibody | Helicore Biopharma | Pre-clinical |
| Antral Gastroplasty / Endoscopic Sleeve | Endo-TAGSS | Pre-clinical |